Syndax Highlights Revuforj® (revumenib) Data Presented at ASCO 2026, Including an Oral Presentation of Post-Transplant Data
Syndax Pharmaceuticals showcased new data at ASCO 2026 demonstrating favorable outcomes for Revuforj (revumenib) as maintenance therapy post hematopoietic stem cell transplant in patients with high-risk acute leukemias. The pooled analysis of 24 patients revealed a 90% two-year overall survival, nearly doubling the historical benchmark of 51%. Addi…